Allied Healthcare Products Inc

Moat Score

Market Cap $800.21
PE -0
Debt $NaN
Cash $5.05M
EV $NaN
FCF -$4.17M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$5.36M
EBIT	-$4.58M
ROE	-102%
ROA	-23%
FCF	-$4.17M
Equity	$5.23M
Growth Stability	1
PE	-0
PB	0
P/FCF	-0
P/S	0
Price/Cash	6.31K
Net Margins	-20%
Gross Margins	9%
Op. Margins	-17%
Sales Growth YoY	-14%
Sales Growth QoQ	-12%
Sales CAGR	-2%
FCF CAGR	0%
Equity CAGR	-14%
Earnings Growth YoY	-225%

Earnings Growth QoQ	51%
Sales CAGR 5Y	-1%
FCF CAGR 5Y	0%
Equity CAGR 5Y	-15%
Earnings CAGR 3Y	-4%
Sales CAGR 3Y	-4%
Equity CAGR 3Y	-14%
Market Cap	$800.21
Revenue	$27.05M
Assets	$19.67M
Cash	$5.05M
Shares Outstanding	4M
Moat Score	2%
Working Capital	10.1M
Current Ratio	2.69
Gross Profit	$2.53M
Shares Growth 3y	-0%
Equity Growth QoQ	-27%
Equity Growth YoY	-51%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Allied Healthcare Products Inc is a US-based company. It mainly manufactures a variety of respiratory products used in the healthcare industry in a wide range of hospital and alternate site settings, including sub-acute care facilities, home health care, and emergency medical care. The product line of the company includes respiratory anesthesia products, home respiratory care products, medical gas system construction products, medical gas system regulation devices, disposable oxygen, and specialty gas cylinders, portable suction equipment, trauma, and patient handling products, respiratory products, and others. The company markets its products under various brand names Timeter, Carbolime, Litholyme, Schuco, Chemetron, Oxequip, Lif-O-Gen, Gomco, and others.

SEC Filings

Direct access to Allied Healthcare Products Inc (AHPIQ) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2022
- 10-K Jun 30
- 10-Q Mar 31
2021
- 10-Q Dec 31
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31
2020
- 10-Q Dec 31
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31

Sector Comparison

How does Allied Healthcare Products Inc compare to its competitors?

Not enough data to generate a comparison chart between Allied Healthcare Products Inc and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Allied Healthcare Products Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Allied Healthcare Products Inc Discounted Cash Flow

Fully customizable DCF calculator online for Allied Healthcare Products Inc.

Years

Calculation mode

= -$43M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$4.2M	-$4.2M	-$4.2M	-$4.2M	-$4.3M	-$4.3M	-$4.3M	-$4.3M	-$4.3M	-$4.4M	-$4.4M	-$44M
DCF		-$3.8M	-$3.5M	-$3.2M	-$2.9M	-$2.7M	-$2.4M	-$2.2M	-$2M	-$1.8M	-$1.7M	-$17M
Value	-$43M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	06/2015	06/2016	06/2017	06/2018	06/2019	06/2020	06/2021	06/2022	TTM
Net Margins	-5%	-6%	-6%	-6%	-7%	-9%	5%	-20%	-20%
ROA	-	-8%	-10%	-12%	-13%	-16%	10%	-23%	-23%
ROE	-	-13%	-13%	-16%	-18%	-34%	16%	-102%	-102%

Bad Net Margins (-19.82%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	06/2015	06/2016	06/2017	06/2018	06/2019	06/2020	06/2021	06/2022	TTM
Debt over FCF	-	-	-	-	0	114.8	-0	-	-
Debt over Equity	-	-	-	-	0	0.38	0	-	-
Growth Stability	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	06/2015	06/2016	06/2017	06/2018	06/2019	06/2020	06/2021	06/2022	CAGR 5Y
Revenue YoY growth	-	1%	-7%	1%	-7%	2%	14%	-25%	-1%
Earnings YoY growth	-	30%	-9%	5%	-4%	43%	-156%	-418%	-
Equity YoY growth	-	-12%	-11%	-14%	-15%	-25%	19%	-51%	-15%
FCF YoY growth	-	-150%	111%	21%	-107%	-50%	-13K%	6%	0%